Research Catalog

Policy issues in the clinical development and use of immunotherapy for cancer treatment : proceedings of a workshop / Erin Balogh, Kimberly Maxfield, Margie Patlak, and Sharyl J. Nass, rapporteurs ; National Cancer Policy Forum, Board on Health Care Services, Health and Medicine Division ; the National Academies of Sciences, Engineering, Medicine.

Title
Policy issues in the clinical development and use of immunotherapy for cancer treatment : proceedings of a workshop / Erin Balogh, Kimberly Maxfield, Margie Patlak, and Sharyl J. Nass, rapporteurs ; National Cancer Policy Forum, Board on Health Care Services, Health and Medicine Division ; the National Academies of Sciences, Engineering, Medicine.
Author
Balogh, Erin
Publication
Washington, DC : National Academies Press, [2016]

Items in the Library & Off-site

Filter by

1 Item

StatusFormatAccessCall NumberItem Location
TextRequest in advance RC271.I45 B35 2016gOff-site

Holdings

Details

Additional Authors
  • Maxfield, Kimberly
  • Patlak, Margie
  • Nass, Sharyl J.
  • National Cancer Policy Forum (U.S.), sponsoring body.
  • Policy Issues in the Clinical Development and Use of Immunotherapy for Cancer Treatment (Workshop) (2016 : Washington, D.C.), author. http://id.loc.gov/vocabulary/relators/aut
Description
xxi, 112 pages : illustrations (some color); 23 cm
Summary
"Immunotherapy is a form of cancer therapy that harnesses the body immune system to destroy cancer cells. In recent years, immunotherapies have been developed for several cancers, including advanced melanoma, lung cancer, and kidney cancer. In some patients with metastatic cancers who have not responded well to other treatments, immunotherapy treatment has resulted in complete and durable responses. Given these promising findings, it is hoped that continued immunotherapy research and development will produce better cancer treatments that improve patient outcomes. With this promise, however, there is also recognition that the clinical and biological landscape for immunotherapies is novel and not yet well understood. For example, adverse events with immunotherapy treatment are quite different from those experienced with other types of cancer therapy. Similarly, immunotherapy dosing, therapeutic responses, and response time lines are also markedly different from other cancer therapies. To examine these challenges and explore strategies to overcome them, the National Academies of Sciences, Engineering, and Medicine held a workshop in February and March of 2016. This report summarizes the presentations and discussions from the workshop"--Publisher's description.
Subjects
Bibliography (note)
  • Includes bibliographical references (pages 94-102).
Contents
Biology of the immune response to tumors -- Cancer immunotherapies -- Drug development challenges for immunotherapies -- Collaboration and information exchange -- Clinical implementation -- Value of immunotherapy.
ISBN
  • 030944232X
  • 9780309442329
OCLC
  • ocn955020058
  • 955020058
  • SCSB-5878709
Owning Institutions
Columbia University Libraries